Gnipst Bulletin 24.4

7/30/2019 Gnipst Bulletin 24.4

1/21

1118-1177-4796-9849-7562-5062mail

GNIPST BULLETIN 2013

26th April 2013 Volume No.: 24 Issue No.: 04

ContentsMessage from GNIPS

Letter to the EditorNews Update

Disease Outbreak Ne

Health Awareness

Forth Coming Events

Drugs Update

Campus News

Students Section

Editors Note

Archive

Vision

TO GROW AS A CENTRE OF EXCELLENCE IN THE FIELD O

PHARMACEUTICAL AND BIOLOGICAL SCIENCE

EDITOR: Debabrata Ghosh DastidarGURU NANAK INSTITUTE OF PHARMACEUTICAL SCIENCE ANDTECHNOLOGY

GNIPST Photo Gallery

For your comments/contributionOR

For Back-Issues,

mailto:[email protected]

1
https://picasaweb.google.com/111714720327580099858/SeminarPresentationmailto:[email protected]:[email protected]:[email protected]://picasaweb.google.com/111714720327580099858/SeminarPresentation


2/21

26-04-2013

MESSAGE FROM GNIPSTAll the members of GNIPST are proud to publish the 23rdVolume of

GNIPST BULLETIN. This bulletin has successfully completed its

twenty months journey. We hope it has kept the readers updated of

recent activities in pharmaceutical & biological sciences and also

introduced them with the different activities of our esteemed

institution. We are thankful to all of you for your great cooperation

& support and are looking forward to the same in future.

LETTER TO THE EDITOR.

NEWS UPDATE

WORLD MALARIA DAY: 25 April, 2013The global campaign theme for World Malaria Day, 2013 and the

coming years is Invest in the future . Defeat malaria. World MalariaDay was instituted by WHO Member States during the 2007

World Health Assembly. It is an occasion to highlight the need for

continued investment and sustained political commitment for

malaria prevention and control. It is also an opportunity for new

donors to join the global malaria partnership, and for research and

academic institutions to showcase their scientific work.Read more

Click here to go at the top1
http://www.who.int/campaigns/malaria-day/2013/event/en/index.htmlhttp://www.who.int/campaigns/malaria-day/2013/event/en/index.htmlhttp://www.who.int/campaigns/malaria-day/2013/event/en/index.htmlhttp://www.who.int/campaigns/malaria-day/2013/event/en/index.html


3/21

26-04-2013

Nanosponges Soak Up Toxins Released by

Bacterial Infections and Venom (14 APRIL 2013)

Engineers have invented a "nanosponge" capable of safely removinga broad class of dangerous toxins from the bloodstream -- including

toxins produced by MRSA, E. coli, poisonous snakes and bees.Readmore

Gene Signature Can Predict Who Will Survive

Chemotherapy (16 APRIL 2013)

An eight gene signature can predict length of relapse-free survival

after chemotherapy, finds new research.Read more

Drinking Cup of Beetroot Juice Daily May Help

Lower Blood Pressure(18APRIL 2013

)A cup of beetroot juice a day may help reduce your blood pressure,

according to a small study.Read moreKey Bone Marrow Protein Identified as Potential

New Leukemia Treatment Target (18 APRIL 2013)

A new study on how the progression of acute lymphocytic leukemia

is influenced by the bone marrow environment has demonstrated

for the first time that targeting a specialized protein known as

http://www.sciencedaily.com/releases/2013/04/130414193435.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/04/130414193435.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/04/130414193435.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/04/130415204819.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/04/130415204819.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/04/130415172230.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/04/130415172230.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/04/130415172230.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/04/130415204819.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/04/130414193435.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/04/130414193435.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29


4/21

26-04-2013

osteopontin may be an effective strategy to increase the efficacy of

chemotherapy in patients with this type of blood cancer.Read moreHigh-Salt Diet and Ulcer Bug Combine to

Increase Risk of Cancer(18 APRIL 2013)

Numerous epidemiologic studies have shown that a diet high in salt

is associated with an increased risk of gastric cancer. Now

researchers have shown that high dietary salt combined with

infection by the ulcer-causing bacterium Helicobacter pylori

greatly increases the risk of cancer.Read moreNanoparticles Found in Everyday Items Can

Inhibit Fat Storage: Gold Nanoparticles

Accelerate Aging. (18 APRIL 2013)

An increase in gold nanoparticles can accelerate aging and

wrinkling, slow wound healing and cause the onset of diabetes.

Read moreBig Boost in Drug Discovery: New Use for Stem

Cells Identifies a Promising Way to Target ALS

(18 APRIL 2013)

Using a new stem-cell based drug screening technology with the

potential to reinvent and greatly reduce the cost of the way new

pharmaceuticals are developed, researchers have found a compound

http://www.sciencedaily.com/releases/2013/04/130415124809.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/04/130415124809.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/04/130415124809.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/04/130418162314.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/04/130418162314.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/04/130418162314.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/04/130418162138.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/04/130418162138.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/04/130418162314.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/04/130415124809.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29


5/21

26-04-2013

more effective in protecting the neurons killed in amyotrophic

lateral sclerosis -- Lou Gehrig's disease -- than two drugs that failed

in human clinical trials after hundreds of millions of dollars had

been invested in them.Read more Low-Dose Aspirin Stymies Proliferation of Two

Breast Cancer Lines (21 APRIL 2013)

Regular use of low-dose aspirin may prevent the progression of

breast cancer, according to a new study.Read moreMicrowave Imaging Can See How Well Treatment

Is Progressing(24 APRIL 2013)

Microwave imaging can be used to monitor how well treatment for

breast cancer is working, finds new research. Microwave

tomography was able to distinguish between breast cancer, benigngrowths, and normal tissue.Read more

Virus Kills Melanoma in Animal Model, Spares

Normal Cells. (24 MARCH 2013)

Researchers have demonstrated that vesicular stomatitis virus is

highly competent at finding, infecting, and killing human melanomacells, both in vitro and in animal models, while having little

propensity to infect non-cancerous cells.Read more.

http://www.sciencedaily.com/releases/2013/04/130418124901.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/04/130418124901.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/04/130421151610.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/04/130421151610.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/04/130423211830.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/04/130423211830.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/04/130423135710.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/04/130423135710.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/04/130423135710.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/04/130423211830.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/04/130421151610.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/04/130418124901.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29


6/21

26-04-2013

HEALTH AWARENESS

MALARIA

According to the latest estimates, there were about 219 million cases of

malaria in 2010 (with an uncertainty range

of 154 million to 289 million) and an

estimated 660 000 deaths (with an

uncertainty range of 490 000 to 836 000).

Malaria mortality rates have fallen by more

than 25% globally since 2000, and by 33% inthe WHO African Region. Most deaths occur among children living in

Africa where a child dies every minute from malaria. Country-level burden

estimates available for 2010 show that an estimated 80% of malaria deaths

occur in just 14 countries and about 80% of cases occur in 17 countries.

Together, the Democratic Republic of the Congo and Nigeria account for

over 40% of the estimated total of malaria deaths globally.

Malaria is caused by Plasmodium parasites. The parasites are spread to

people through the bites of infected Anopheles mosquitoes, called "malaria

vectors", which bite mainly between dusk and dawn.

There are four parasite species that cause malaria in humans:

Plasmodium falciparum

Plasmodium vivax

Plasmodium malariae

Plasmodium ovale.



7/21

26-04-2013

Plasmodium falciparum and Plasmodium vivax are the most common.

Plasmodium falciparum is the most deadly.

In recent years, some human cases of malaria have also occurred with

Plasmodium knowlesi a species that causes malaria among monkeys and

occurs in certain forested areas of South-East Asia.

Transmission

Malaria is transmitted exclusively through the bites of Anopheles

mosquitoes. The intensity of transmission depends on factors related to the

parasite, the vector, the human host, and the environment.

About 20 different Anopheles species are locally important around the

world. All of the important vector species bite at night. Anopheles

mosquitoes breed in water and each species has its own breeding

preference; for example some prefer shallow collections of fresh water, such

as puddles, rice fields, and hoof prints. Transmission is more intense in

places where the mosquito lifespan is longer (so that the parasite has time

to complete its development inside the mosquito) and where it prefers to

bite humans rather than other animals. For example, the long lifespan and

strong human-biting habit of the African vector species is the main reason

why more than 90% of the world's malaria deaths are in Africa.

Transmission also depends on climatic conditions that may affect the

number and survival of mosquitoes, such as rainfall patterns, temperature

and humidity. In many places, transmission is seasonal, with the peak



8/21

26-04-2013

during and just after the rainy season. Malaria epidemics can occur when

climate and other conditions suddenly favour transmission in areas where

people have little or no immunity to malaria. They can also occur when

people with low immunity move into areas with intense malariatransmission, for instance to find work, or as refugees.

Human immunity is another important factor, especially among adults in

areas of moderate or intense transmission conditions. Partial immunity is

developed over years of exposure, and while it never provides complete

protection, it does reduce the risk that malaria infection will cause severe

disease. For this reason, most malaria deaths in Africa occur in young

children, whereas in areas with less transmission and low immunity, all age

groups are at risk.

Symptoms

Malaria is an acute febrile illness. In a non-immune individual, symptoms

appear seven days or more (usually 1015 days) after the infective mosquito

bite. The first symptoms fever, headache, chills and vomiting may be

mild and difficult to recognize as malaria. If not treated within 24 hours, P.

falciparum malaria can progress to severe illness often leading to death.

Children with severe malaria frequently develop one or more of the

following symptoms: severe anaemia, respiratory distress in relation to

metabolic acidosis, or cerebral malaria. In adults, multi-organ involvementis also frequent. In malaria endemic areas, persons may develop partial

immunity, allowing asymptomatic infections to occur.



9/21

26-04-2013

For both P. vivax and P. ovale, clinical relapses may occur weeks to months

after the first infection, even if the patient has left the malarious area. These

new episodes arise from dormant liver forms known as hypnozoites (absent

in P. falciparum and P. malariae); special treatment targeted at these liverstages is required for a complete cure.

Who is at risk?

Approximately half of the world's population is at risk of malaria. Most

malaria cases and deaths occur in sub-Saharan Africa. However, Asia, Latin

America, and to a lesser extent the Middle East and parts of Europe are also

affected. In 2011, 99 countries and territories had ongoing malaria

transmission.

Specific population risk groups include:

young children in stable transmission areas who have not yet

developed protective immunity against the most severe forms of the

disease;

non-immune pregnant women as malaria causes high rates of

miscarriage and can lead to maternal death;

semi-immune pregnant women in areas of high transmission. Malaria

can result in miscarriage and low birth weight, especially during first

and second pregnancies;

semi-immune HIV-infected pregnant women in stable transmission

areas, during all pregnancies. Women with malaria infection of the

placenta also have a higher risk of passing HIV infection to their

newborns;



10/21

26-04-2013

people with HIV/AIDS;

international travellers from non-endemic areas because they lack

immunity;

immigrants from endemic areas and their children living in non-

endemic areas and returning to their home countries to visit friends

and relatives are similarly at risk because of waning or absent

immunity.

Diagnosis and treatment

Early diagnosis and treatment of malaria reduces disease and prevents

deaths. It also contributes to reducing malaria transmission.

The best available treatment, particularly for P. falciparum malaria, is

artemisinin-based combination therapy (ACT).

WHO recommends that all cases of suspected malaria be confirmed using

parasite-based diagnostic testing (either microscopy or rapid diagnostic

test) before administering treatment. Results of parasitological

confirmation can be available in 15 minutes or less. Treatment solely on the

basis of symptoms should only be considered when a parasitological

diagnosis is not possible. More detailed recommendations are available in

the Guidelines for the treatment of malaria (second edition).

Antimalarial drug resistance

Resistance to antimalarial medicines is a recurring problem. Resistance of

P. falciparum to previous generations of medicines, such as chloroquine and



11/21

26-04-2013

sulfadoxine-pyrimethamine (SP), became widespread in the 1970s and

1980s, undermining malaria control efforts and reversing gains in child

survival.

In recent years, parasite resistance to artemisinins has been detected in four

countries of the Greater Mekong subregion: Cambodia, Myanmar, Thailand

and Viet Nam. While there are likely many factors that contribute to the

emergence and spread of resistance, the use of oral artemisinins alone, as

monotherapy, is thought to be an important driver. When treated with an

oral artemisinin-based monotherapy, patients may discontinue treatment

prematurely following the rapid disappearance of malaria symptoms. This

results in incomplete treatment, and such patients still have persistent

parasites in their blood. Without a second drug given as part of a

combination (as is provided with an ACT), these resistant parasites survive

and can be passed on to a mosquito and then another person.

If resistance to artemisinins develops and spreads to other large

geographical areas, the public health consequences could be dire, as no

alternative antimalarial medicines will be available for at least five years.

WHO recommends the routine monitoring of antimalarial drug resistance,

and supports countries to strengthen their efforts in this important area of

work.

More comprehensive recommendations are available in the WHO Global

Plan for Artemisinin Resistance Containment (GPARC), which was

released in 2011.



12/21

26-04-2013

Prevention

Vector control is the main way to reduce malaria transmission at the

community level. It is the only intervention that can reduce malaria

transmission from very high levels to close to zero.

For individuals, personal protection against mosquito bites represents the

first line of defence for malaria prevention.

Two forms of vector control are effective in a wide range of circumstances.Insecticide-treated mosquito nets (ITNs)

Long-lasting insecticidal nets (LLINs) are the preferred form of ITNs for

public health distribution programmes. WHO recommends coverage for all

at-risk persons; and in most settings. The most cost effective way to achieve

this is through provision of free LLINs, so that everyone sleeps under a LLIN

every night.

Indoor spraying with residual insecticides

Indoor residual spraying (IRS) with insecticides is a powerful way to

rapidly reduce malaria transmission. Its full potential is realized when at

least 80% of houses in targeted areas are sprayed. Indoor spraying is

effective for 36 months, depending on the insecticide used and the type ofsurface on which it is sprayed. DDT can be effective for 912 months in some

cases. Longer-lasting forms of existing IRS insecticides, as well as new

classes of insecticides for use in IRS programmes, are under development.



13/21

26-04-2013

Antimalarial medicines can also be used to prevent malaria. For travellers,

malaria can be prevented through chemoprophylaxis, which suppresses the

blood stage of malaria infections, thereby preventing malaria disease. In

addition, WHO recommends intermittent preventive treatment withsulfadoxine-pyrimethamine for pregnant women living in high

transmission areas, at each scheduled antenatal visit after the first

trimester. Similarly, for infants living in high-transmission areas of Africa, 3

doses of intermittent preventive treatment with sulfadoxine-

pyrimethamine is recommended delivered alongside routine vaccinations.

In 2012, WHO recommended Seasonal Malaria Chemoprevention as an

additional malaria prevention strategy for areas of the Sahel sub-Region of

Africa. The strategy involves the administration of monthly courses of

amodiaquine plus sulfadoxine-pyrimethamine to all children under 5 years

of age during the high transmission season.

Insecticide resistance

Much of the success to date in controlling malaria is due to vector control.

Vector control is highly dependent on the use of pyrethroids, which are the

only class of insecticides currently recommended for ITNs or LLINs. In

recent years, mosquito resistance to pyrethroids has emerged in many

countries. In some areas, resistance to all four classes of insecticides used

for public health has been detected. Fortunately, this resistance has only

rarely been associated with decreased efficacy, and LLINs and IRS remainhighly effective tools in almost all settings.

However, countries in sub-Saharan Africa and India are of significant

concern. These countries are characterized by high levels of malaria



14/21

26-04-2013

transmission and widespread reports of insecticide resistance. The

development of new, alternative insecticides is a high priority and several

promising products are in the pipeline.. Development of new insecticides

for use on bed nets is a particular priority.

Detection of insecticide resistance should be an essential component of all

national malaria control efforts to ensure that the most effective vector

control methods are being used. The choice of insecticide for IRS should

always be informed by recent, local data on the susceptibility target vectors.

In order to ensure a timely and coordinated global response to the threat of

insecticide resistance, WHO has worked with a wide range of stakeholders

to develop the Global Plan for Insecticide Resistance Management in

malaria vectors (GPIRM), which was released in May 2012. The GPIRM

puts forward a five-pillar strategy calling on the global malaria community

to:

plan and implement insecticide resistance management strategies in

malaria-endemic countries;

ensure proper and timely entomological and resistance monitoring,

and effective data management;

develop new and innovative vector control tools;

fill gaps in knowledge on mechanisms of insecticide resistance and the

impact of current insecticide resistance management approaches; and

ensure that enabling mechanisms (advocacy as well as human and

financial resources) are in place.



15/21

26-04-2013

Surveillance

Tracking progress is a major challenge in malaria control. Malaria

surveillance systems detect only around 10% of the estimated global

number of cases. Stronger malaria surveillance systems are urgently needed

to enable a timely and effective malaria response in endemic regions, to

prevent outbreaks and resurgences, to track progress, and to hold

governments and the global malaria community accountable. In April 2012,

the WHO Director-General launched new global surveillance manuals for

malaria control and elimination, and urged endemic countries to strengthentheir surveillance systems for malaria. This was embeddedpart of in a larger

call to scale up diagnostic testing, treatment and surveillance for malaria,

known as WHOs T3: Test. Treat. Track initiative.

Elimination

Malaria elimination is defined as interrupting local mosquito-borne malaria

transmission in a defined geographical area, i.e. zero incidence of locally

contracted cases. Malaria eradication is defined as the permanent reduction

to zero of the worldwide incidence of malaria infection caused by a specific

agent; i.e. applies to a particular malaria parasite species.

Many countries especially in temperate and sub-tropical zones have

been successful in eliminating malaria. The global malaria eradicationcampaign, launched by WHO in 1955, was successful in eliminating the

disease in some countries, but ultimately failed to achieve its overall goal,

thus being abandoned less than two decades later in favour of the less



16/21

26-04-2013

ambitious goal of malaria control. In recent years, however, interest in

malaria eradication as a long-term goal has re-emerged.

Large-scale use of WHO-recommended strategies, currently available tools,strong national commitments, and coordinated efforts with partners, will

enable more countries particularly those where malaria transmission is

low and unstable to progress towards malaria elimination. In recent years,

4 countries have been certified by the WHO Director-General as having

eliminated malaria: United Arab Emirates (2007), Morocco (2010),

Turkmenistan (2010), and Armenia (2011).

Vaccines against malaria

There are currently no licensed vaccines against malaria or any other human

parasite. One research vaccine against P. falciparum, known as RTS,S/AS01,

is most advanced. This vaccine is currently being evaluated in a large

clinical trial in 7 countries in Africa. A WHO recommendation for use will

depend on the final results from the large clinical trial. These final results

are expected in late 2014, and a recommendation as to whether or not this

vaccine should be added to existing malaria control tools is expected in

2015

DISEASE OUTBREAK NEWS

FORTHCOMING EVENTS



17/21

26-04-2013

DRUGS UPDATES

FDA launches partnership to protect against

counterfeit anti-malarial medicines with FDA-

developed handheld detection tool

(24 APRIL 2013)

The U.S. FDA announced a public-private partnership to help

identify counterfeit or substandard anti-malarial medicines,

including falsified products, with the deployment of the FDA-

developed Counterfeit Detection Device, called CD-3.Read more FDA approves abuse-deterrent labeling for

reformulated OxyContin. (16 APRIL 2013)

approved updated labeling for Purdue Pharma L.P.s reformulated

OxyContin (oxycodone hydrochloride controlled-release) tablets.

The new labeling indicates that the product has physical and

chemical properties that are expected to make abuse via injection

difficult and to reduce abuse via the intranasal route (snorting).

Read more.

http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm349195.htmhttp://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm349195.htmhttp://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm348252.htmhttp://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm348252.htmhttp://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm348252.htmhttp://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm349195.htm


18/21

26-04-2013

CAMPUS NEWS

The farewell ceremony for the final year students will be organized

in the first week of May, 2013.

STUDENTS SECTION

WHO CAN ANSWER FIRST???() Name of which fruit in English was derived

from Arabic Naranj ?

() According to Chinese legend, what did empressShiling Ti discovered in her tea cup while

sitting under a tree?Answer of Previous Issue Question:

A) Strychnine B)Lupin Ltd. Send your thoughts/ Quiz/Puzzles/games/write-ups or any other contributions for Students Section

& answers of this Section at [email protected]

mailto:[email protected]:[email protected]:[email protected]


19/21

26-04-2013

EDITORS NOTE

I am very happy to publish the 4th issue of 24th Volume of GNIPST

BULLETIN. It is my great pleasure to introduce you to the newlylaunched facebook account GNIPST bulletin. You are cordially

invited to add this account to your friend list. The current issues will

also be directly available on facebook.

I would like to convey my thanks to all the GNIPST members and

the readers for their valuable comments, encouragement& supports.

Special thanks to Dr. Prerona Saha for her advice; Mr. Soumya

Bhattacharya, for his contribution instudents section.

It would be my great pleasure to receive the contributions,

suggestions & feedback from your desk for further upliftment of this

deliberation GNIPST BULLETIN.



20/21

26-04-2013

ARCHIVE

The general body meeting of APTI, Bengal Branch has been

conducted at GNIPST on 15th June, 2012. The programme started

with a nice presentation by Dr. Pulok Kr. Mukherjee, School of

Natural Products, JU on the skill to write a good manuscript for

publication in impact journals. It was followed by nearly two hour

long discussion among more than thirty participants on different

aspects of pharmacy education. Five nonmember participants

applied for membership on that very day.

GNIPST is now approved by AICTE and affiliated to WBUT forconducting the two years post graduate course (M.Pharm) in

PHARMACOLOGY. The approved number of seat is 18.

The number of seats in B.Pharm. has been increased from 60 to 120.

2nd World Congress on Ga-68 (Generators and Novel Radiopharmaceuticals),

Molecular Imaging (PET/CT), Targeted Radionuclide Therapy, and Dosimetry

(SWC-2013) : On the Way to Personalized Medicine

Dates 28 Feb 2013 02 Mar 2013



21/21

26-04-2013

Location: Chandigarh, India.Details.

AICTE has sanctioned a release of grant under Research

Promotion Scheme (RPS) during the financial year 2012-13to GNIPST as per the details below:

a. Beneficiary Institution: Guru Nanak Institution of

Pharmaceutical Science & Technology.

b. Principal Investigator: Dr. LopamudraDutta.

c. Grant-in-aid sanctioned:Rs. 16,25000/- only

d. Approved duration: 3 years

e.Title of the project: Screening and identification of potential

medicinal plant ofPurulia&Bankuradistricts of West Bengal with

respect to diseases such as diabetes, rheumatism, Jaundice,

hypertension and developing biotechnological tools for enhancing

bioactive molecules in these plant.
http://www.2ndworldcongress-ga-68.de/http://www.2ndworldcongress-ga-68.de/http://www.2ndworldcongress-ga-68.de/http://www.2ndworldcongress-ga-68.de/

Gnipst Bulletin 24.4

Documents

Transcript of Gnipst Bulletin 24.4